We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.
- Authors
Evans, Sherryn; Newton, Richard; Higgins, Sally
- Abstract
Objective : Olanzapine is the most commonly prescribed atypical antipsychotic medication in Australia. Research reports an average weight gain of between 4.5 and 7 kg in the 3 months following its commencement. Trying to minimize this weight gain in a population with an already high prevalence of obesity, mortality and morbidity is of clinical and social importance. This randomized controlled trial investigated the impact of individual nutrition education provided by a dietitian on weight gain in the 3 and 6 months following the commencement of olanzapine. Method : Fifty-one individuals (29 females, 22 males) who had started on olanzapine in the previous 3 months (mean length of 27 days ± 20) were recruited through Peninsula Health Psychiatric Services and were randomly assigned to either the intervention (n = 29) or the control group (n = 22). Individuals in the intervention group received six 1 hour nutrition education sessions over a 3-month period. Weight, waist circumference, body mass index (BMI) and qualitative measures of exercise levels, quality of life, health and body image were collected at baseline at 3 and 6 months. Results : After 3 months, the control group had gained significantly more weight than the treatment group (6.0 kg vs 2.0 kg, p ≤ 0.002). Weight gain of more than 7% of initial weight occurred in 64% of the control group compared to 13% of the treatment group. The control group's BMI increased significantly more than the treatment group's (2 kg/m2 vs 0.7 kg/m2, p ≤ 0.03). The treatment group reported significantly greater improvements in moderate exercise levels, quality of life, health and body image compared to the controls. At 6 months, the control group continued to show significantly more weight gain since baseline than the treatment group (9.9 kg vs 2.0 kg, p ≤ 0.013) and consequently had significantly greater increases in BMI (3.2 kg/m2 vs 0.8 kg/m2, p ≤ 0.017). Conclusion : Individual nutritional intervention provided by a dietitian is highly successful at preventing olanzapine-induced weight gain. Australian and New Zealand Journal of Psychiatry 2005; 39:479–486
- Publication
Australian & New Zealand Journal of Psychiatry, 2005, Vol 39, Issue 6, p479
- ISSN
0004-8674
- Publication type
Academic Journal
- DOI
10.1111/j.1440-1614.2005.01607.x